From: Rotarix: A Rotavirus Vaccine for the World

Slides:

Advertisements

Similar presentations

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:

Advertisements

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 1. Baseline Characteristics of the 36,636 Study Subjects

Volume 370, Issue 9601, Pages (November 2007)

Figure 1. Disposition of study participants, by group. Data are no

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

Laboratory diagnosis and biosafety issues of biological warfare agents

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Table 1 Criteria for proven invasive fungal disease except for endemic mycoses. From: Revised Definitions of Invasive Fungal Disease from the European.

From: Postinfectious Irritable Bowel Syndrome

Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Approach to diagnosis of infective endocarditis

Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America

Varicella vaccination: a laboured take-off

Herpes zoster in non-hospitalized children

Gastroenteritis outbreak caused by norovirus associated with the children's club of a hotel located in Majorca, Spain A. Doménech-Sánchez Clinical Microbiology.

Large increase of rotavirus diarrhoea in the hospital setting associated with emergence of G12 genotype in a highly vaccinated population in Nicaragua

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

P.L. Lopalco, P. Carrillo Santisteve

Training for the infectious diseases speciality in Norway

Rotavirus vaccination: a concise review

Retrospective study of CMV retinitis in patients with AIDS

Laboratory diagnosis and biosafety issues of biological warfare agents

Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes S. Ladhani,

Viruses causing gastroenteritis

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

A. Bryskier Clinical Microbiology and Infection

Identification of risk factors associated with nosocomial infection by rotavirus P4G2, in a neonatal unit of a tertiary-care hospital R. Herruzo, F.

Training in infectious diseases and tropical medicine in Britain

Vaccinations against respiratory tract infections at Hajj

Clinical infection services—the Leiden experience

Clinical Microbiology and Infection

Clinical Microbiology and Infection

W. Eugene Sanders, Christine C. Sanders

Overview of cefixime use in community-acquired infections

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Genomic diversity of group A rotavirus strains in patients aged 1–36 months admitted for acute watery diarrhoea in northern India: a hospital-based study

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study R. Goering, C.-E. Nord, R.

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

Decision-making in otitis media in children, Part I: epidemiologic data and definitions for a reliable cost-effectiveness analysis Bernard Grenier Clinical.

Rotavirus Vaccines An Update

Presentation transcript:

From: Rotarix: A Rotavirus Vaccine for the World Table 3 Summary of major trials of the RIX4414 vaccine. From: Rotarix: A Rotavirus Vaccine for the World Clin Infect Dis. 2009;48(2):222-228. doi:10.1086/595702 Clin Infect Dis | © 2009 by the Infectious Diseases Society of America

From: Rotarix: A Rotavirus Vaccine for the World Table 2 Efficacy of the RIX4414 vaccine against severe rotavirus gastroenteritis or rotavirus gastroenteritis of any severity over 2 years in 6 European countries. From: Rotarix: A Rotavirus Vaccine for the World Clin Infect Dis. 2009;48(2):222-228. doi:10.1086/595702 Clin Infect Dis | © 2009 by the Infectious Diseases Society of America

From: Rotarix: A Rotavirus Vaccine for the World Table 1 Efficacy of the RIX4414 vaccine against severe gastroenteritis or hospitalization for gastroenteritis in 11 Latin American countries. From: Rotarix: A Rotavirus Vaccine for the World Clin Infect Dis. 2009;48(2):222-228. doi:10.1086/595702 Clin Infect Dis | © 2009 by the Infectious Diseases Society of America

From: Rotarix: A Rotavirus Vaccine for the World Figure 1 Cumulative cases of definite intussusception (IS) during the weeks after administration of either the first or second dose of the RIX4414 vaccine (31,673 recipients) or placebo (31,552 recipients) in 11 Latin American countries and Finland. From: Rotarix: A Rotavirus Vaccine for the World Clin Infect Dis. 2009;48(2):222-228. doi:10.1086/595702 Clin Infect Dis | © 2009 by the Infectious Diseases Society of America